Publications by authors named "Pedro Such"

Claim this Profile
D
Developing Topics.
Anton P Porsteinsson, Sanjeda R Chumki, Anton M Palma, Malaak Brubaker, David Wang, Pedro Such

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing Topics.
Anton P Porsteinsson, Sanjeda R Chumki, Anton M Palma, David Wang, Pedro Such

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analysis for Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder.
Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S Bell Lynum, Frank Larsen, Pedro Such

Clin Pharmacol Drug Dev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial.
Alpesh Shah, Alvin Estilo, Pamela L Sheridan, Uwa Kalu, Dalei Chen, Pedro Such

CNS Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding patient, caregiver, and prescriber preferences for an antipsychotic regimen administered once every 2 months for schizophrenia or bipolar I disorder: a qualitative interview study in North America.
Roger S McIntyre, Murat Yildirim, Stephanie Loomer, Clodagh Beckham, Dawn Bates, Pedro Such

Curr Med Res Opin· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases.
Frank Andersohn, Pedro Such, Michael Jan, Uwa Kalu, Jessica McDonough

Ther Adv Psychopharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brexpiprazole for agitation in clinically relevant patient subgroups: a analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease.
Jared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, Pedro Such, David Wang

Curr Med Res Opin· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Patient, Caregiver, and Prescriber Preferences for an Injectable Antipsychotic Administered Every 2 Months for the Maintenance Treatment of Schizophrenia: A Multicenter Qualitative Interview Study Conducted in Europe.
Sofia Pappa, Murat Yildirim, Stephanie Loomer, Clodagh Beckham, Dawn Bates, Pedro Such

Patient Prefer Adherence· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia.
Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham

Ther Adv Psychopharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii) in people with bipolar I disorder: a Plain Language Summary of Publication.
Roger S McIntyre, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Na Jin

Ther Adv Psychopharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham

J Clin Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
Roger S McIntyre, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Zhen Zhang

Curr Med Res Opin· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Pedro Such

Neuropsychiatr Dis Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan

CNS Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
John M Kane, Bruce J Kinon, Carlos Forray, Pedro Such, Aurélia Mittoux

Schizophr Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia.
Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori

Eur Neuropsychopharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
Olivier Rascol, Rossella Medori, Corine Baayen, Pedro Such, Didier Meulien

Mov Disord· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia.
Pedro Such, Martin Bøg, Madhu S Kabra, Kristian T Jørgensen, Anne C de Jong-Laird

Prim Care Companion CNS Disord· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.
Pedro Such, José Manuel Olivares, Lizbeth Arias, Mette Troels Berg, Jessica Madera

Neuropsychiatr Dis Treat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of disease in early schizophrenia - a systematic literature review.
Benedicto Crespo-Facorro, Pedro Such, Anna-Greta Nylander, Jessica Madera, Henrike K Resemann

Curr Med Res Opin· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment.
Jessica Madera, Pedro Such, Peter Zhang, Ross A Baker, Iria Grande

Neuropsychiatr Dis Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies.
Timothy Peters-Strickland, Ross A Baker, Pedro Such, Peter Zhang, Jessica J Madera

Neuropsychiatr Dis Treat· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies.
Jessica J Madera, Pedro Such, Cathy Zhao, Ross A Baker

Neuropsychiatr Dis Treat· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Pedro Such

J Affect Disord· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
Joseph R Calabrese, Na Jin, Brian Johnson, Pedro Such, Ross A Baker

Int J Bipolar Disord· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis